Stocktwits on MSN
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum
The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. ・CEO Angelos ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events ...
SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for ...
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML ...
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) has surged over 200% over the last six months, with a year-to-date stock jump of around 45%. The cancer drug developer Sellas Life Sciences could be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results